Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Etrumadenant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-928 is under development for the treatment of solid tumors including metastatic triple negative breast cancer, bladder cancer, rectal cancer, endometrial cancer, head and neck squamous cell carcinoma, melanoma, merkel cell carcinoma, pancreatic ductal adenocarcinoma, metastatic castration-resistant prostate cancer, metastatic ovarian cancer, metastatic gastroesophageal cancer, colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. The drug candidate is administered orally. It acts by targeting adenosine receptor 2a and adenosine receptor 2b.
Arcus Biosciences overview
Arcus Biosciences operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. The company has in-house specialization in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. Arcus Biosciences is headquartered in Hayward, California, the US.
For a complete picture of Etrumadenant’s drug-specific PTSR and LoA scores, buy the report here.